New drugs for paediatrics, dermatology, oncology on the anvil: Dr Reddys

Compound E7777 is intended to be used in the treatment of Cutaneous T Cell Lymphoma while DFD-29 (Low dose minocycline) is aimed at Papulopustular rosacea, it said.

"Approval-enabling study is on. Submission of a biologics licencee application to the US FDA is planned in 2021," the drug-maker said in case of E7777.

"As of March 31, 2020, we have had four late-stage projects at various stages of development ranging from products that have completed Phase-2 clinical trials to products that are undergoing investigation for US FDA approval," the city-based drug-maker said in a regulatory filing.

"In addition, we have multiple other programmes in the early stages of development (i.e. exploratory stage through Phase-2) in the pipeline," the company said.

The revenues from the proprietary products segment were Rs 795 crorefor the year-ended March 31, 2020, an increase of 67 percent as compared to Rs 475 crore with the corresponding period previous year," it said.